

Risk Assessment, Genetic Counseling, and Genetic Testing for *BRCA*-Related Cancer

US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force

IMPORTANCE Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (*BRCA1/2*) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general population, *BRCA1/2* mutations occur in an estimated 1 in 300 to 500 women and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases.






OBJECTIVE To update the 2013 US Preventive Services Task Force (USPSTF) recommendation on risk assessment, genetic counseling, and genetic testing for *BRCA*-related cancer.

EVIDENCE REVIEW The USPSTF reviewed the evidence on risk assessment, genetic counseling, and genetic testing for potentially harmful *BRCA1/2* mutations in asymptomatic women who have never been diagnosed with *BRCA*-related cancer, as well as those with a previous diagnosis of breast, ovarian, tubal, or peritoneal cancer who have completed treatment and are considered cancer free. In addition, the USPSTF reviewed interventions to reduce the risk for breast, ovarian, tubal, or peritoneal cancer in women with potentially harmful *BRCA1/2* mutations, including intensive cancer screening, medications, and risk-reducing surgery.

FINDINGS For women whose family or personal history is associated with an increased risk for harmful mutations in the *BRCA1/2* genes, or who have an ancestry associated with *BRCA1/2* gene mutations, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are moderate. For women whose personal or family history or ancestry is not associated with an increased risk for harmful mutations in the *BRCA1/2* genes, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are small to none. Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic counseling, genetic testing, and interventions are small to moderate.

CONCLUSIONS AND RECOMMENDATION The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with *BRCA1/2* gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing. (B recommendation) The USPSTF recommends against routine risk assessment, genetic counseling, or genetic testing for women whose personal or family history or ancestry is not associated with potentially harmful *BRCA1/2* gene mutations. (D recommendation)

JAMA. 2019;322(7):652-665. doi:10.1001/jama.2019.10987
Last corrected on November 12, 2019.

-  [Editorial page 619](#)
-  [Author Audio Interview](#)
-  [Related article page 666 and JAMA Patient Page page 702](#)
-  [CME Quiz at \[jamanetwork.com/learning\]\(http://jamanetwork.com/learning\)](#)
-  [Related articles at \[jamaoncology.com\]\(http://jamaoncology.com\), \[jamasurgery.com\]\(http://jamasurgery.com\), and \[jamanetworkopen.com\]\(http://jamanetworkopen.com\)](#)

Corresponding Author: Douglas K. Owens, MD, MS, Stanford University, 616 Serra St, Encina Hall, Room C336, Stanford, CA 94305-6019 (chair@uspstf.net).

The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.

It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.

The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.

Summary of Recommendations and Evidence

The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (*BRCA1/2*) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing (B recommendation) (Figure 1).

The USPSTF recommends against routine risk assessment, genetic counseling, or genetic testing for women whose personal or family history or ancestry is not associated with potentially harmful *BRCA1/2* gene mutations. (D recommendation)

Rationale

Importance

Potentially harmful mutations of the *BRCA1/2* genes are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer.¹⁻⁶ For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death.⁷ In the general population, *BRCA1/2* mutations occur in an estimated 1 in 300 to 500 women and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases.⁸⁻¹¹ A woman's risk for breast cancer increases if she has clinically significant mutations in the *BRCA1/2* genes.^{12,13} Mutations in the *BRCA1/2* genes increase breast cancer risk to 45% to 65% by age 70 years. Risk of ovarian, fallopian tube, or peritoneal cancer increases to 39% for *BRCA1* mutations and 10% to 17% for *BRCA2* mutations.^{12,13}

Detection

Genetic risk assessment and *BRCA1/2* mutation testing is a multi-step process that begins with identifying patients with family or personal histories of breast, ovarian, tubal, or peritoneal cancer; family members with known harmful *BRCA1/2* mutations; or ancestry associated with harmful *BRCA1/2* mutations. Risk for clinically significant *BRCA1/2* mutations can be further evaluated with genetic counseling by suitably trained health care clinicians, followed by genetic testing of selected high-risk individuals and posttest counseling about results. The USPSTF found adequate evidence that familial risk assessment tools are accurate in identifying women with increased like-

lihood of *BRCA1/2* mutations. These tools can be used by primary care clinicians to guide referrals to genetic counseling.

The USPSTF has previously established that there is adequate evidence that current genetic tests can accurately detect known *BRCA1/2* mutations.¹⁴

Benefits of Screening, Genetic Counseling, and Genetic Testing

The USPSTF found adequate evidence that the benefits of risk assessment, genetic counseling, and genetic testing are moderate in women whose family history is associated with an increased risk for harmful mutations in the *BRCA1/2* genes.

The USPSTF found adequate evidence that the benefits of risk assessment, genetic counseling, and genetic testing are small to none in women whose family history is not associated with an increased risk for harmful mutations in the *BRCA1/2* genes.

Harms of Screening, Genetic Counseling, and Genetic Testing

The USPSTF found adequate evidence that the harms associated with risk assessment, genetic counseling, genetic testing, and interventions are small to moderate.

USPSTF Assessment

The USPSTF concludes with moderate certainty that the net benefit of risk assessment for increased risk of *BRCA1/2* mutations, testing for *BRCA1/2* mutations, and use of risk-reducing interventions outweighs the harms in women whose family or personal history is associated with an increased risk for potentially harmful mutations in the *BRCA1/2* genes.

The USPSTF concludes with moderate certainty that the harms of risk assessment for increased risk of *BRCA1/2* mutations, testing for *BRCA1/2* mutations, and use of risk-reducing interventions outweigh the benefits in women whose family or personal history is not associated with an increased risk for potentially harmful mutations in the *BRCA1/2* genes.

Clinical Considerations

Patient Population Under Consideration

This recommendation applies to women who are asymptomatic for *BRCA*-related cancer and have unknown *BRCA* mutation status (Figure 2). It includes women who have never been diagnosed with *BRCA*-related cancer, as well as those with a previous breast, ovarian, tubal, or peritoneal cancer diagnosis who have completed treatment and are considered cancer free but have not been previously tested. While this recommendation applies to women, the net benefit estimates are driven by biological sex (ie, male/female) rather than gender identity. Persons should consider their sex at birth to determine which recommendation best applies to them.

Assessment of Risk

Mutations in the *BRCA1/2* genes cluster in families, showing an autosomal dominant pattern of inheritance in either the mother's or father's family. When taking medical and family history information from patients, primary care clinicians should ask about specific types of cancer, primary cancer sites, which family members were

Figure 1. USPSTF Grades and Levels of Evidence

What the USPSTF Grades Mean and Suggestions for Practice		
Grade	Definition	Suggestions for Practice
A	The USPSTF recommends the service. There is high certainty that the net benefit is substantial.	Offer or provide this service.
B	The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or there is moderate certainty that the net benefit is moderate to substantial.	Offer or provide this service.
C	The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.	Offer or provide this service for selected patients depending on individual circumstances.
D	The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.	Discourage the use of this service.
I statement	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.	Read the Clinical Considerations section of the USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.

USPSTF Levels of Certainty Regarding Net Benefit	
Level of Certainty	Description
High	The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.
Moderate	The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as the number, size, or quality of individual studies. inconsistency of findings across individual studies. limited generalizability of findings to routine primary care practice. lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
Low	The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of the limited number or size of studies. important flaws in study design or methods. inconsistency of findings across individual studies. gaps in the chain of evidence. findings not generalizable to routine primary care practice. lack of information on important health outcomes. More information may allow estimation of effects on health outcomes.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.	

USPSTF indicates US Preventive Services Task Force.

affected, and whether relatives had multiple types of primary cancer. Clinicians should also inquire about the age at diagnosis, age at death, and sex of affected family members, both immediate (ie, parents and siblings) as well as more distant (ie, aunts, uncles, grandparents, and cousins).

For women who have family members with breast, ovarian, tubal, or peritoneal cancer or have a personal history of these types of cancer, primary care clinicians may use appropriate brief familial risk assessment tools to determine the need for in-depth genetic counseling. Tools evaluated by the USPSTF include the Ontario Family History Assessment Tool (Table 1), Manchester Scoring System (Table 2), Referral Screening Tool (Table 3), Pedigree Assessment

Tool (Table 4), 7-Question Family History Screening Tool (Table 5), International Breast Cancer Intervention Study instrument (Tyre-Cuzick) (Table 6), and brief versions of BRCAPRO. Each of these tools has been validated and accurately estimate the likelihood of carrying a harmful *BRCA1/2* mutation. They can be used to guide referrals to genetic counseling for more definitive risk assessment.²⁸ General breast cancer risk assessment models (eg, the National Cancer Institute Breast Cancer Risk Assessment Tool, which is based on the Gail model) are not designed to identify *BRCA*-related cancer risk and should not be used for this purpose.

In general, these brief familial risk assessment tools include factors associated with increased likelihood of potentially harmful

Figure 2. Clinical Summary: Risk Assessment, Genetic Counseling, and Genetic Testing for *BRCA*-Related Cancer

Population	Women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with <i>BRCA1/2</i> gene mutations	Women whose personal or family history or ancestry is not associated with potentially harmful <i>BRCA1/2</i> gene mutations
Recommendation	Assess with an appropriate brief familial risk assessment tool. Grade: B	Do not perform routine risk assessment, genetic counseling, or genetic testing. Grade: D

Risk Assessment	Patients with family or personal histories of breast, ovarian, tubal, or peritoneal cancer or ancestry associated with harmful <i>BRCA1/2</i> mutations should be assessed using a familial risk assessment tool. The USPSTF found adequate evidence that these tools are accurate in identifying women with increased likelihood of <i>BRCA1/2</i> mutations. Tools evaluated by the USPSTF include the Ontario Family History Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree Assessment Tool, 7-Question Family History Screening Tool, International Breast Cancer Intervention Study instrument (Tyrer-Cuzick), and brief versions of BRCAPRO. These tools should be used to guide referrals to genetic counseling.
Genetic Counseling	Genetic counseling about <i>BRCA1/2</i> mutation testing should be performed by trained health professionals, including suitably trained primary care providers. The process of genetic counseling includes detailed kindred analysis and risk assessment for potentially harmful <i>BRCA1/2</i> mutations. It also includes identification of candidates for testing, patient education, discussion of the benefits and harms of genetic testing, interpretation of results after testing, and discussion of management options.
Genetic Testing	Tests for <i>BRCA1/2</i> mutations are highly sensitive and specific for known mutations. Testing for <i>BRCA1/2</i> mutations should be performed when an individual has personal or family history that suggests an inherited cancer susceptibility, when an individual is willing to see a health professional who is suitably trained to provide genetic counseling and interpret test results, and when test results will aid in decision making.
Treatment and Interventions	In general, the care of women with harmful <i>BRCA1/2</i> mutations is managed with a variety of interventions to lower future cancer risk. This includes intensive screening, risk-reducing medications, and risk-reducing mastectomy and salpingo-oophorectomy.
Relevant USPSTF Recommendations	The USPSTF recommends that clinicians offer to prescribe risk-reducing medications such as tamoxifen, raloxifene, or aromatase inhibitors to women at increased risk for breast cancer and at low risk for adverse medication effects. It recommends against the routine use of medications for risk reduction of primary breast cancer in women not at increased risk for breast cancer. The USPSTF recommends against screening for ovarian cancer in women. This recommendation does not apply to women with known genetic mutations that increase their risk for ovarian cancer (eg, <i>BRCA1/2</i> mutations). The USPSTF found insufficient evidence to assess the balance of benefits and harms of performing screening pelvic examinations in asymptomatic women for the early detection and treatment of a range of gynecologic conditions.

For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to <https://www.uspreventiveservicestaskforce.org>.



BRCA indicates breast cancer susceptibility gene; USPSTF, US Preventive Services Task Force.

BRCA1/2 mutations. These include breast cancer diagnosis before age 50 years, bilateral breast cancer, presence of both breast and ovarian cancer in one individual, male family members with breast cancer, multiple cases of breast cancer in the family, 1 or more family members with 2 primary types of *BRCA*-related cancer (such as ovarian cancer), and Ashkenazi Jewish ancestry. The USPSTF recognizes that each risk assessment tool has advantages and limitations and found insufficient evidence to recommend one over another.

Genetic Counseling

The process of genetic counseling includes detailed kindred analysis and risk assessment for potentially harmful *BRCA1/2* mutations. It also includes identification of candidates for testing, patient education, discussion of the benefits and harms of genetic testing, interpretation of results after testing, and discussion of management options. Genetic counseling about *BRCA1/2* mutation testing

should be performed by trained health professionals, including suitably trained primary care clinicians. Several professional organizations describe the skills and training necessary to provide comprehensive genetic counseling.

Genetic Testing

Testing for *BRCA1/2* mutations should be performed only when an individual has personal or family history that suggests an inherited cancer susceptibility, when an individual is willing to talk with a health professional who is suitably trained to provide genetic counseling and interpret test results, and when test results will aid in decision-making. Clinical practice guidelines recommend that *BRCA1/2* mutation testing begin with a relative with known *BRCA*-related cancer, including male relatives, to determine if a clinically significant mutation is detected in the family before testing individuals without cancer.²⁹ If an affected family member with a *BRCA*-related cancer is not available, then the relative with the highest probability of

Table 1. Ontario Family History Assessment Tool^a

Risk Factor	Points
Breast and ovarian cancer	
Mother	10
Sibling	7
Second-/third-degree relative	5
Breast cancer relatives	
Parent	4
Sibling	3
Second-/third-degree relative	2
Male relative (add to above)	2
Breast cancer characteristics	
Onset age, y	
20-29	6
30-39	4
40-49	2
Premenopausal/perimenopausal	2
Bilateral/multifocal	3
Ovarian cancer relatives	
Mother	7
Sibling	4
Second-/third-degree relative	3
Ovarian cancer onset age, y	
<40	6
40-60	4
>60	2
Prostate cancer onset	
Age <50 y	1
Colon cancer onset	
Age <50 y	1
Family total	
Referral ^b	≥10

^a See Gilpin et al,¹⁵ Oros et al,¹⁶ Panchal et al,¹⁷ Parmigiani et al.¹⁸

^b Referral with score of 10 or greater corresponds to doubling of lifetime risk for breast cancer (22%).

mutation should be tested. The type of mutation analysis required depends on family history. Individuals from families with known mutations or from ancestry groups in which certain mutations are more common (eg, Ashkenazi Jewish founder mutations) can be tested for these specific mutations. Because risk assessment is primarily based on family history, it is unclear how women with a limited or unknown family history should be assessed for *BRCA1/2* mutation risk and potential referral to counseling or genetic testing.

Tests for *BRCA1/2* mutations are highly sensitive and specific for known mutations. The availability of testing options has changed since the 2013 US Supreme Court ruling that determined human genes are not patentable (*Association for Molecular Pathology et al v Myriad Genetics Inc et al*).³⁰ Previously, *BRCA1/2* mutation testing in the United States was mainly conducted by 1 laboratory. Since the ruling, the number of testing options has significantly increased, with more than 80 multigene panels that include *BRCA1/2*, as well as tests marketed directly to consumers.³¹

Guidelines from the American College of Medical Genetics and Genomics, which were updated in 2015, recommend new stan-

Table 2. Manchester Scoring System^{a,b}

Risk Factor (Age at Onset for Relative in Direct Lineage)	<i>BRCA1</i> Score	<i>BRCA2</i> Score
Female breast cancer, y		
<30	6	5
30-39	4	4
40-49	3	3
50-59	2	2
≥60	1	1
Male breast cancer, y		
<60	5 ^c	8 ^d
≥60	5 ^c	5 ^d
Ovarian cancer, y		
<60	8	5
≥60	5	5
Pancreatic cancer		
Any age	0	1
Prostate cancer, y		
<60	0	2
≥60	0	1
Total individual genes	10	10
Total for combined = 15		

Abbreviation: *BRCA*, breast cancer susceptibility gene.

^a See Oros et al,¹⁶ Parmigiani et al,¹⁸ Antoniou et al,¹⁹ Barcnas et al,²⁰ Evans et al.²¹

^b A score of 10 in either column or a combined score of 15 for both columns would be equivalent to a 10% chance of identifying a *BRCA1* or *BRCA2* mutation.

^c If testing for *BRCA2*.

^d If testing for *BRCA1*.

standard terminology for reporting *BRCA1/2* mutations identified by genetic tests. These include a 5-tier terminology system using the terms "pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign."³²

Treatment and Interventions

Management of increased cancer risk related to *BRCA1/2* mutations is beyond the scope of this Recommendation Statement. In general, care for women with harmful *BRCA1/2* mutations consists of a variety of interventions to lower future cancer risk. This includes intensive screening, risk-reducing medications, and risk-reducing mastectomy and salpingo-oophorectomy.

Additional Tools and Resources

The National Cancer Institute Cancer Genetics Services Directory provides a list of professionals who offer services related to cancer genetics, including cancer risk assessment, genetic counseling, and genetic testing.³³

Other Related USPSTF Recommendations

The USPSTF recommends that clinicians offer to prescribe risk-reducing medications such as tamoxifen, raloxifene, or aromatase inhibitors to women at increased risk for breast cancer and at low

risk for adverse medication effects (B recommendation). It recommends against the routine use of medications for risk reduction of primary breast cancer in women not at increased risk for breast cancer (D recommendation).³⁴

The USPSTF recommends against screening for ovarian cancer in women (D recommendation). This recommendation does not apply to women with known genetic mutations that increase their risk for ovarian cancer (eg, *BRCA1/2* mutations).³⁵ The USPSTF found insufficient evidence to assess the balance of benefits and harms of performing screening pelvic examinations in asymptomatic women for the early detection and treatment of a range of gynecologic conditions (I statement).³⁶

Other Considerations

Research Needs and Gaps

Research on risk assessment and testing for *BRCA1/2* mutations has focused on short-term outcomes for highly selected women in referral centers. To determine the best approaches for population-based risk assessment and testing, more research is needed about mutation prevalence and effects on the general population as well as ethnicities or ancestries associated with *BRCA1/2* mutations. Because risk assessment is primarily based on family history, more research is needed to better understand how women with an unknown family history should be assessed for *BRCA1/2* mutation risk. Additional studies are needed, including comparative effectiveness trials, of approaches to risk screening and strategies to improve access to genetic counseling, as well as *BRCA1/2* testing for high-risk individuals.

It would be helpful to understand which methods of delivery of genetic counseling are most effective, including those that can increase access to genetic counseling in rural or other settings with limited access. Trials comparing types of clinicians and protocols could address these questions. The consequences of genetic testing for individuals and their relatives require more study. Well-designed investigations using standardized measures and diverse study populations are needed.

An expanded database or registry of patients receiving genetic counseling for inherited breast and ovarian cancer susceptibility or who are tested for *BRCA1/2* mutations would provide useful information about predictors of cancer and response to interventions. Additional data are needed from women of varying socioeconomic and racial/ethnic groups.

For women who are *BRCA1/2* mutation carriers, studies about the effectiveness of intensive cancer screening and risk-reducing medications and the effects of age at intervention on improving long-term outcomes are needed. This research would increase knowledge of the relative benefits and harms of interventions that are provided on the basis of genetic risk information.

Discussion

Burden of Disease

For women, breast cancer is the most common cancer in the United States after nonmelanoma skin cancer and the second leading cause of cancer death.³⁷ In 2017, an estimated 252 710 women were diag-

Table 3. Referral Screening Tool^{a,b}

History of Breast or Ovarian Cancer in the Family? If Yes, Complete Checklist		
Risk Factor	Breast Cancer at Age ≤50 y	Ovarian Cancer at any Age
Yourself		
Mother		
Sister		
Daughter		
Mother's side		
Grandmother		
Aunt		
Father's side		
Grandmother		
Aunt		
≥2 cases of breast cancer after age 50 y on same side of family		
Male breast cancer at any age in any relative		
Jewish ancestry		

^a See Bellcross et al.²²

^b Referral if 2 or more checks in table.

Table 4. Pedigree Assessment Tool^{a,b}

Risk Factor	Score for Every Family Member With Breast or Ovarian Cancer Diagnosis, Including Second-/Third-Degree Relatives
Breast cancer at age ≥50 y	3
Breast cancer at age <50 y	4
Ovarian cancer at any age	5
Male breast cancer at any age	8
Ashkenazi Jewish heritage	4
Total	

^a See Hoskins et al,²³ Teller et al.²⁴

^b Score 8 or greater is the optimal referral threshold.

nosed with breast cancer in the United States and 40 610 died of the disease.³⁷ Ovarian cancer is the fifth leading cause of cancer death in women in the United States.³⁷ In 2017, an estimated 22 440 women were diagnosed with ovarian cancer and 14 080 died of the disease.³⁷ Mutations of the *BRCA1/2* genes are estimated to occur in 1 in 300 to 500 women in the general population⁸⁻¹¹ and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases.^{9,11,38}

Estimates of the prevalence of potentially harmful *BRCA1/2* mutations vary by population. The estimated prevalence is 0.2% to 0.3% in the general population of women, 6.0% in women with cancer onset before age 40 years, and 2.1% in the general population of Ashkenazi Jewish women.³⁹ In a meta-analysis of studies in which recruitment was based on family history of breast or ovarian cancer, *BRCA1* mutation prevalence was 13.6%, *BRCA2* mutation prevalence was 7.9%, and prevalence of either mutation was 19.8%.³⁹

Scope of Review

To update its 2013 recommendation, the USPSTF commissioned a systematic review^{28,40} on risk assessment, genetic counseling, and genetic testing for potentially harmful *BRCA1/2* mutations in

Table 5. Seven-Question Family History Screening^{a,b}

No.	Questions
1	Did any of your first-degree relatives have breast or ovarian cancer?
2	Did any of your relatives have bilateral breast cancer?
3	Did any man in your family have breast cancer?
4	Did any woman in your family have breast <i>and</i> ovarian cancer?
5	Did any woman in your family have breast cancer before age 50 y?
6	Do you have 2 or more relatives with breast <i>and/or</i> ovarian cancer?
7	Do you have 2 or more relatives with breast <i>and/or</i> bowel cancer?

^a See Ashton-Prolla et al,²⁵ Fischer et al.²⁶

^b One positive response initiates referral.

Table 6. International Breast Cancer Intervention Study Model^{a,b}

No.	Risk Factor
1	Personal history: current age, age at menopause, age at menarche, childbirth history, menopausal status, use of menopausal hormone therapy
2	Personal breast history, breast density (optional), prior breast biopsy, history of cancer (breast or ovarian), genetic testing
3	Ashkenazi Jewish inheritance
4	Family history (genetic risk)—relatives with breast or ovarian cancer, age at diagnosis, genetic testing

^a See Fischer et al,²⁶ Cuzick.²⁷

^b Referral for genetic testing if the personal risk level for a mutation in breast cancer susceptibility gene 1 or 2 is 10% or greater.

asymptomatic women who have never been diagnosed with *BRCA*-related cancer, as well as those with a previous breast, ovarian, tubal, or peritoneal cancer diagnosis who have completed treatment and are considered cancer free. The USPSTF reviewed interventions to reduce the risk for breast, ovarian, tubal, or peritoneal cancer in women with potentially harmful *BRCA1/2* mutations, including intensive cancer screening (eg, earlier and more frequent mammography or magnetic resonance imaging [MRI] of the breast), medications (eg, tamoxifen, raloxifene, or aromatase inhibitors), and risk-reducing surgery (eg, mastectomy or salpingo-oophorectomy). Although male breast cancer, pancreatic cancer, prostate cancer, and melanoma are associated with *BRCA1/2* mutations, discussion of these types of cancer is outside the scope of this recommendation.

Accuracy of Familial Risk Assessment

The USPSTF reviewed studies of familial risk stratification tools that could be used in primary care settings to determine the likelihood of potentially harmful *BRCA1/2* mutations. These tools are primarily intended for use by health care clinicians untrained in genetic cancer risk assessment to guide referral to genetic counselors for more definitive evaluation. In general, these tools elicit information about factors associated with increased likelihood of *BRCA1/2* mutations, including family and personal history of cancer (including types of cancer and age of diagnosis) and ancestry (Ashkenazi Jewish). Because risk assessment is primarily based on family history, it is unclear how women with an unknown family history should be assessed for *BRCA1/2* mutation risk.

Models that have been validated in studies include the Ontario Family History Assessment Tool (Table 1),¹⁵⁻¹⁸ Manchester Scoring System (Table 2),^{16-21,41} Referral Screening Tool (Table 3),²² Pedigree Assessment Tool (Table 4),^{23,24} 7-Question Family History Screening Tool (Table 5),²⁵ and the International Breast Cancer Intervention Study instrument (also known as Tyrer-Cuzick) (Table 6), and their variations.²⁶ The USPSTF found that these tools are clinically useful predictors of which individuals should be referred for genetic counseling. Compared with results of other models or genetic testing in studies, these tools all have sensitivity estimates between 77% and 100% and areas under the receiver operating characteristic curve between 0.68 and 0.96,²⁸ although some models have been evaluated in only 1 study.^{22,25,26} The USPSTF reviewed a study of brief versions of BRCAPRO (eg, BRCAPRO-LYTE), designed for primary care clinicians, followed by the full BRCAPRO (used by genetic counselors) and found that the sequential testing scheme identified a similar number of *BRCA* mutation carriers as the full BRCAPRO.⁴² The USPSTF recognizes that each risk assessment tool has advantages and limitations and found insufficient evidence to recommend one tool over another.

Effectiveness of Genetic Counseling, Genetic Testing, and Interventions

To understand the full benefits and harms of genetic counseling, the USPSTF reviewed studies on pretest and posttest counseling, *BRCA1/2* mutation testing, and interventions.

Pretest and Posttest Counseling

The USPSTF reviewed 28 studies on pretest counseling.⁴³⁻⁷² Studies reported measures of distress associated with genetic counseling for *BRCA*-related cancer, including cancer worry (17 studies), anxiety (13 studies), and depression (7 studies). In general, pretest genetic counseling either decreased or had no effect on breast cancer worry, anxiety, and depression.²⁸ Twenty-two studies examined understanding of risk, with most reporting either improved understanding (14 studies)^{45,48,53,55-58,61,64,65,67-69,72,73} or no association (6 studies),^{43,52,59,62,70,71} 1 study reporting decreased understanding,⁶⁰ and 1 study reporting mixed results.⁴⁶ Five studies that evaluated the effects of genetic counseling on *BRCA1/2* mutation testing intention found decreased intent to test in 4 studies^{45,53,58,67} and increased intent in 1 study.⁷⁴

Although several studies included discussion of management options as part of the pretest counseling process, none evaluated benefits or harms of counseling conducted after receiving test results.

BRCA1/2 Mutation Testing

One good-quality trial (n = 1034) of women and men of Ashkenazi Jewish ancestry evaluated population-based *BRCA1/2* mutation testing vs family history-based testing.⁷⁵ Results showed that a strategy of population-based testing for founder mutations detected more *BRCA1/2* mutation carriers than testing persons who met family history criteria. However, no clinical outcomes were reported and, because not all participants had *BRCA1/2* mutation testing, the accuracy of this strategy could not be determined. Genetic testing generally improved risk perception, with increased perceived risk of breast and ovarian cancer risk in *BRCA1/2* mutation carriers and decreased perceived risk in persons testing negative.^{76,77}

Interventions

Studied interventions to reduce risk for cancer in women who are *BRCA1/2* mutation carriers include earlier, more frequent, or more intensive cancer screening (eg, breast MRI or mammography); use of risk-reducing medications (eg, selective estrogen receptor modulators or aromatase inhibitors); and risk-reducing surgery (eg, mastectomy or salpingo-oophorectomy).

The USPSTF reviewed 11 randomized clinical trials of selective estrogen receptor modulators and aromatase inhibitors, although none were conducted specifically in women who were *BRCA1/2* mutation carriers. Results of meta-analysis⁷⁸ indicated clinically significant reductions in invasive breast cancer with the use of tamoxifen, raloxifene, and aromatase inhibitors, with 7 fewer events per 1000 women for tamoxifen (4 trials),⁷⁹⁻⁸² 9 fewer events per 1000 women for raloxifene (2 trials),^{83,84} and 16 fewer events per 1000 women for aromatase inhibitors (2 trials),⁸⁵⁻⁸⁹ assuming 5 years of treatment. Tamoxifen reduced invasive breast cancer more than raloxifene in the head-to-head trial (relative risk, 1.24 [95% CI, 1.05-1.47]).⁹⁰ Risk reduction persisted at least 8 years after discontinuation in the 2 tamoxifen trials providing long-term follow-up data. All medications reduced estrogen receptor-positive, but not estrogen receptor-negative, invasive breast cancer. Breast cancer-specific and all-cause mortality were not reduced.⁷⁸

In cohort studies of high-risk women and women who were *BRCA1/2* mutation carriers, risk-reducing surgery such as mastectomy (6 studies),⁹¹⁻⁹⁷ oophorectomy (7 studies),⁹⁸⁻¹⁰⁴ or salpingo-oophorectomy (2 studies)^{91,105} were associated with reduced risk for breast or ovarian cancer. Bilateral mastectomy was associated with a 90% to 100% reduced breast cancer incidence and 81% to 100% reduced breast cancer mortality. Oophorectomy was associated with 81% to 100% reduced ovarian cancer incidence. In general, there was no association between oophorectomy or salpingo-oophorectomy and reduced breast cancer risk, although some studies showed reduced risk in younger women (age <50 years).^{78,98,99}

The USPSTF found no studies on the benefits of intensive screening for *BRCA*-related cancer on clinical outcomes in women who are *BRCA1/2* mutation carriers.

Harms of Genetic Counseling, Genetic Testing, and Interventions

The USPSTF reviewed the psychological effects of test results. Nine studies evaluated breast cancer worry or distress after genetic testing. Increased worry was found in 7 studies,^{77,106-111} particularly in women who are *BRCA1/2* mutation carriers, and 2 studies reported decreased worry.^{112,113} Studies reporting anxiety related to genetic testing were mixed, with 4 reporting increased anxiety,^{106,109,113,114} 2 reporting decreased anxiety,^{111,115} and 6 reporting no association.^{75,108,112,116-118} Two studies noted higher anxiety in women who were not tested compared with those who were tested.^{111,119} Of the 8 studies evaluating depression, none reported increases in anxiety after genetic testing.^{75,108,111,112,115,117,118,120}

Intensive screening for breast and ovarian cancer is associated with false-positive results, additional imaging tests, and surgery for women without cancer. In a retrospective analysis of a cohort of women with potentially harmful *BRCA1/2* mutations or first-degree relatives with *BRCA1/2* mutations, women screened with mammography were more likely to have additional imaging tests than

those screened with MRI.¹²¹ In 2 studies comparing mammography with MRI for breast cancer screening in which 18% to 100% of study participants were *BRCA1/2* mutation carriers, MRI was associated with higher false-positive rates (14% vs 5.5% in the first round of screening; $P < .001$ ¹²²; 15% vs 11% in another study¹²¹). Intensive screening for ovarian cancer using transvaginal ultrasound demonstrated high false-positive rates (3.4%).¹²³ A second study in women who were *BRCA1/2* mutation carriers reported a diagnostic surgery rate of 55% after annual screening with transvaginal ultrasound and serum tumor marker cancer antigen 125 measurements for women without cancer.¹²⁴ Most women did not experience anxiety after screening with MRI, mammography, or clinical breast examination, although women recalled for additional testing reported transient anxiety.¹²⁵

Eight placebo-controlled trials and 1 head-to-head trial of tamoxifen and raloxifene reported harms of risk-reducing medications. Raloxifene and tamoxifen increased risk for thromboembolic events compared with placebo, and raloxifene caused fewer events than tamoxifen in the head-to-head trial.^{78,126,127} An increased risk of endometrial cancer was seen with tamoxifen (4 cases per 1000 women) but not with raloxifene or aromatase inhibitors. Women using tamoxifen had more cataract procedures compared with placebo or raloxifene.^{79,90} The most common adverse effects were vasomotor symptoms and vaginal discharge, itching, or dryness for tamoxifen and vasomotor symptoms and leg cramps for raloxifene.²⁸

Thirteen studies of mastectomy¹²⁸⁻¹⁴⁰ and 9 studies of oophorectomy or salpingo-oophorectomy¹⁴¹⁻¹⁴⁵ reported harms associated with surgical interventions, although most were small in size and had mixed outcomes. For mastectomy, complication rates ranged from 49% to 69%.²⁸ Complications included numbness, pain, tingling, infection, swelling, breast hardness, bleeding, organizing hematoma, failed reconstruction, breathing problems, thrombosis, and pulmonary embolism.²⁸ Postsurgical complications associated with oophorectomy/salpingo-oophorectomy included bleeding, pain, infection, and hematoma formation, with 1% to 3% of women in 1 study reporting such complications.¹⁴² In another small study of women who were *BRCA1/2* mutation carriers, most women reported worsening vasomotor symptoms and decreased sexual function.¹⁴⁶ Seven studies reported psychological outcomes in women receiving risk-reducing mastectomy¹³²⁻¹⁴⁰ and 3 studies in those receiving risk-reducing oophorectomy/salpingo-oophorectomy.¹⁴³⁻¹⁴⁵ Commonly reported symptoms included reductions in body image, sexual activity/satisfaction, and general mental health (anxiety/depression symptoms); however, many of these symptoms were transient.²⁸

Estimate of Magnitude of Net Benefit

For women whose family or personal history is associated with an increased risk for harmful mutations in the *BRCA1/2* genes, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are moderate. For women whose family history is not associated with an increased risk for harmful mutations in the *BRCA1/2* genes, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are small to none.

The USPSTF found adequate evidence that the overall harms of risk assessment, genetic counseling, genetic testing, and interventions are small to moderate.

For women whose family history is associated with an increased risk for harmful mutations in the *BRCA1/2* genes, the USPSTF concludes with moderate certainty that the net benefit outweighs the harm of risk assessment and referral to genetic counseling for consideration of testing, detection, and intervention is moderate. For women whose family history is not associated with an increased risk for harmful mutations in the *BRCA1/2* genes, the USPSTF concludes with moderate certainty that the harms of risk assessment and referral to genetic counseling for consideration of testing, detection, and intervention outweigh the benefits.

How Does the Evidence Fit With Biological Understanding?

The *BRCA1* and *BRCA2* genes are tumor suppressor genes. Harmful mutations of these genes have been linked to hereditary breast and ovarian cancer. Risks for breast, ovarian, and other types of *BRCA*-related cancer are greatly increased in patients who have inherited potentially harmful *BRCA1/2* mutations. Genetic testing may identify these mutations. Several options are available to reduce cancer risk in patients found to be mutation carriers.

Response to Public Comment

A draft version of this Recommendation Statement was posted for public comment on the USPSTF website from February 19 through March 18, 2019. In response to public comments, the USPSTF clarified language regarding risk assessment and included additional information on the risk assessment tools referenced in the recommendation. It also incorporated language clarifying that the recommendation includes women with a personal history of *BRCA*-related cancer who have completed treatment and are considered cured.

Comments requested that the population under consideration be expanded to include other *BRCA*-associated cancers such as pancreatic cancer, melanoma, and prostate cancer, as well as men with breast or prostate cancer. The USPSTF recognizes the association of *BRCA1/2* mutations with cancers such as pancreatic, prostate, and melanoma. However, the scope of the recommendation is limited to the prevention of breast, ovarian, tubal, and peritoneal cancer because the net benefit demonstrated was in the prevention of these cancers. The USPSTF did not review evidence on the benefits or harms of risk assessment, genetic counseling, and genetic testing in men.

Several comments requested changes to the recommendation related to newer genetic testing options. This includes the use of multigene panels, expanding the recommendation to include other gene mutations linked to increased risk of cancer (eg, *TP53*, *ATM*, *PALB2*), and the use of direct-to-consumer testing. The USPSTF acknowledges that there is increasing access to multigene panels; however, the clinical significance of identifying pathogenic variants in multigene panels requires further investigation. The evidence is currently limited on other moderate penetrance genes, given their relatively low incidence in the population. The USPSTF's recommendation focuses on *BRCA1/2* mutations because they are more prevalent and the findings are clinically actionable. The USPSTF found no evidence on the benefits or harms associated with the use of direct-to-consumer testing. Current National Comprehensive Cancer Network guidelines recommend that multigene testing be offered in the context of professional genetic expertise for pretest and posttest.²⁹ The USPSTF added language emphasizing that the net benefit

relies on genetic counseling to accompany testing results, including results from direct-to-consumer testing.

Update of Previous USPSTF Recommendation

In 2005 and 2013, the USPSTF recommended that women whose family history is associated with an increased risk for potentially harmful mutations in the *BRCA1/2* genes be referred for genetic counseling and evaluation for *BRCA1/2* testing. It also recommended against routine referral for genetic counseling or routine *BRCA1/2* mutation testing for women whose family history is not associated with an increased risk for potentially harmful mutations in the *BRCA1/2* genes.^{14,147} This Recommendation Statement is consistent with the USPSTF's previous recommendation.

Since 2013, the validity of genetic testing for *BRCA1/2* mutations has been established and the potential benefits and harms of previously reviewed interventions, such as risk-reducing medications and surgery, have been studied for longer follow-up periods. In addition, there have been more studies of newer imaging techniques (breast MRI), surgical procedures (salpingo-oophorectomy rather than oophorectomy alone), and medications (aromatase inhibitors). The updated recommendation expands the population eligible for screening to include women with a previous breast, ovarian, tubal, or peritoneal cancer diagnosis who have completed treatment and are considered cancer free and more explicitly includes ancestry associated with *BRCA1/2* mutations (ie, founder mutations) as a risk factor.

Recommendations of Others

The National Comprehensive Cancer Network provides specific criteria for genetic counseling and testing.²⁹ The American College of Medical Genetics and the American Society of Clinical Oncology recommend testing for *BRCA1/2* mutations only when an individual has personal or family cancer history suggestive of inherited cancer susceptibility, the test can be adequately interpreted, and the results will aid in management.^{148,149} The American College of Obstetricians and Gynecologists recommends performing a hereditary cancer risk assessment and subsequent referral to a specialist in cancer genetics if necessary.¹⁵⁰ The Society for Gynecologic Oncology recommends that individuals with a likelihood of inherited predisposition to cancer based on personal or family history should be offered genetic counseling.¹⁵¹ The American Society of Breast Surgeons recommends that genetic testing be made available to all patients with a personal history of breast cancer.¹⁵² The National Institute for Health and Care Excellence recommends that health care professionals respond to a patient who presents with concerns but should not, in most instances, actively seek to identify persons with a family history of breast cancer.¹⁵³ It recommends that in some circumstances, including when a patient has concerns about relatives with breast cancer, a first- and second-degree family history be taken in primary care to assess risk. Referral to secondary care is recommended if risk factors are identified in family history taking.¹⁵³ The European Society for Medical Oncology follows the recommendations of the National Institute for Health and Care Excellence for initial risk assessment and the decision when to perform genetic counseling and testing.¹⁵⁴

ARTICLE INFORMATION

Correction: This article was corrected on October 11, 2019, for incorrect information in an author affiliation and on November 12, 2019, for an incorrect word that affected the meaning of a sentence.

The US Preventive Services Task Force (USPSTF) members: Douglas K. Owens, MD, MS; Karina W. Davidson, PhD, MASc; Alex H. Krist, MD, MPH; Michael J. Barry, MD; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Chyke A. Doubeni, MD, MPH; John W. Epling Jr, MD, MEd; Martha Kubik, PhD, RN; C. Seth Landefeld, MD; Carol M. Mangione, MD, MSPH; Lori Pbert, PhD; Michael Silverstein, MD, MPH; Melissa A. Simon, MD, MPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.

Affiliations of The US Preventive Services Task Force (USPSTF) members: Veterans Affairs Palo Alto Health Care System, Palo Alto, California (Owens); Stanford University, Stanford, California (Owens); Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York (Davidson); Fairfax Family Practice Residency, Fairfax, Virginia (Krist); Virginia Commonwealth University, Richmond (Krist); Harvard Medical School, Boston, Massachusetts (Barry); University of California, San Francisco (Cabana); Oregon Health & Science University, Portland (Caughey); Mayo Clinic, Rochester, Minnesota (Doubeni); Virginia Tech Carilion School of Medicine, Roanoke (Epling Jr); Temple University, Philadelphia, Pennsylvania (Kubik); University of Alabama at Birmingham (Landefeld); University of California, Los Angeles (Mangione); University of Massachusetts Medical School, Worcester (Pbert); Boston University, Boston, Massachusetts (Silverstein); Northwestern University, Evanston, Illinois (Simon); University of Hawaii, Honolulu (Tseng); Pacific Health Research and Education Institute, Honolulu, Hawaii (Tseng); Tufts University School of Medicine, Boston, Massachusetts (Wong).

Author Contributions: Dr Owens had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Authors followed the policy regarding conflicts of interest described at <https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures>. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.

Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.

Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.

Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.

Additional Contributions: We thank Justin Mills, MD, MPH (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicoletta, MA (AHRQ), who assisted with coordination and editing.

REFERENCES

- Brody LC, Biesecker BB. Breast cancer susceptibility genes: *BRCA1* and *BRCA2*. *Medicine (Baltimore)*. 1998;77(3):208-226. doi:10.1097/00005792-199805000-00006
- Mersch J, Jackson MA, Park M, et al. Cancers associated with *BRCA1* and *BRCA2* mutations other than breast and ovarian. *Cancer*. 2015;121(2):269-275. doi:10.1002/cncr.29041
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science*. 1994;266(5182):66-71. doi:10.1126/science.7545954
- Wooster R, Weber BL. Breast and ovarian cancer. *N Engl J Med*. 2003;348(23):2339-2347. doi:10.1056/NEJMra012284
- Sherman ME, Piedmonte M, Mai PL, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group trial GOG-0199. *J Clin Oncol*. 2014;32(29):3275-3283. doi:10.1200/JCO.2013.54.1987
- Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with *BRCA1* and *BRCA2* mutations. *Cancer*. 2010;116(22):5261-5271. doi:10.1002/cncr.25439
- American Cancer Society (ACS). Cancer Facts & Figures 2018. ACS website. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html>. Published 2018. Accessed July 3, 2019.
- Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. *Genet Epidemiol*. 2000;18(2):173-190. doi:10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R
- Anglian Breast Cancer Study Group. Prevalence and penetrance of *BRCA1* and *BRCA2* mutations in a population-based series of breast cancer cases. *Br J Cancer*. 2000;83(10):1301-1308. doi:10.1054/bjoc.2000.1407
- Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating *BRCA1*, *BRCA2* and other genes. *Br J Cancer*. 2002;86(1):76-83. doi:10.1038/sj.bjc.6600008
- Peto J, Collins N, Barfoot R, et al. Prevalence of *BRCA1* and *BRCA2* gene mutations in patients with early-onset breast cancer. *J Natl Cancer Inst*. 1999;91(11):943-949. doi:10.1093/jnci/91.11.943
- Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet*. 2003;72(5):1117-1130. doi:10.1086/375033
- Chen S, Parmigiani G. Meta-analysis of *BRCA1* and *BRCA2* penetrance. *J Clin Oncol*. 2007;25(11):1329-1333. doi:10.1200/JCO.2006.09.1066
- Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for *BRCA*-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;160(4):271-281. doi:10.7326/M13-2747
- Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. *Clin Genet*. 2000;58(4):299-308. doi:10.1034/j.1399-0004.2000.580408.x
- Oros KK, Ghadirian P, Maugard CM, et al. Application of *BRCA1* and *BRCA2* mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. *Clin Genet*. 2006;70(4):320-329. doi:10.1111/j.1399-0004.2006.00673.x
- Panchal SM, Ennis M, Canon S, Bordeleau LJ. Selecting a *BRCA* risk assessment model for use in a familial cancer clinic. *BMC Med Genet*. 2008;9:116. doi:10.1186/1471-2350-9-116
- Parmigiani G, Chen S, Iversen ES Jr, et al. Validity of models for predicting *BRCA1* and *BRCA2* mutations. *Ann Intern Med*. 2007;147(7):441-450. doi:10.7326/0003-4819-147-7-200710020-00002
- Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a *BRCA1* or *BRCA2* mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. *J Med Genet*. 2008;45(7):425-431. doi:10.1136/jmg.2007.056556
- Barcenas CH, Hosain GM, Arun B, et al. Assessing *BRCA* carrier probabilities in extended families. *J Clin Oncol*. 2006;24(3):354-360. doi:10.1200/JCO.2005.02.2368
- Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a *BRCA1/2* mutation outperforms existing models including BRCAPRO. *J Med Genet*. 2004;41(6):474-480. doi:10.1136/jmg.2003.017996
- Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. *Genet Med*. 2009;11(11):783-789. doi:10.1097/GIM.0b013e3181b9b04a
- Hoskins KF, Zwaagstra A, Ranz M. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. *Cancer*. 2006;107(8):1769-1776. doi:10.1002/cncr.22202
- Teller P, Hoskins KF, Zwaagstra A, et al. Validation of the pedigree assessment tool (PAT) in families with *BRCA1* and *BRCA2* mutations. *Ann Surg Oncol*. 2010;17(1):240-246. doi:10.1245/s10434-009-0697-9
- Ashton-Prolla P, Giacomazzi J, Schmidt AV, et al. Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care. *BMC Cancer*. 2009;9:283. doi:10.1186/1471-2407-9-283
- Fischer C, Kuchenbäcker K, Engel C, et al; German Consortium for Hereditary Breast and Ovarian Cancer. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting *BRCA1/2* mutation carrier probabilities: a study based on

- 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. *J Med Genet*. 2013; 50(6):360-367. doi:10.1136/jmedgenet-2012-101415
27. Cuzick J. IBIS Breast Cancer Risk Evaluation Tool, v8. <http://www.ems-trials.org/friskevaluator/>. 2017. Accessed July 25, 2019.
28. Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L. *Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: A Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 182*. Rockville, MD: Agency for Healthcare Research and Quality; 2019. AHRQ publication 19-05251-EF-1.
29. National Comprehensive Cancer Network (NCCN). Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Published 2012. Accessed July 3, 2019.
30. *Association for Molecular Pathology et al v Myriad Genetics Inc et al*, 133 S Ct 2107 (June 13, 2013).
31. Petrucelli N, Daly MB, Pal T. *BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer*. Seattle: University of Washington; 2016.
32. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. doi:10.1038/gim.2015.30
33. National Cancer Institute (NCI). NCI Cancer Genetics Services Directory. NCI website. <https://www.cancer.gov/about-cancer/causes-prevention/genetics/directory>. Accessed July 3, 2018.
34. Moyer VA; U.S. Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2013;159(10):698-708.
35. Grossman DC, Curry SJ, Owens DK, et al; US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(6):588-594. doi:10.1001/jama.2017.21926
36. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for gynecologic conditions with pelvic examination: US Preventive Services Task Force recommendation statement. *JAMA*. 2017;317(9):947-953. doi:10.1001/jama.2017.0807
37. American Cancer Society (ACS). Cancer Facts & Figures 2018. 2018; <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf>. Accessed November 19, 2018.
38. Whittemore AS, Gong G, John EM, et al. Prevalence of *BRCA1* mutation carriers among U.S. non-Hispanic whites. *Cancer Epidemiol Biomarkers Prev*. 2004;13(12):2078-2083.
39. Nelson HD, Fu R, Goddard K, et al. *Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis No. 101*. Rockville, MD: Agency for Healthcare Research and Quality; 2013. AHRQ publication 12-05164-EF-1.
40. Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk assessment, genetic counseling, and genetic testing for *BRCA*-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force [published August 20, 2019]. *JAMA*. doi:10.1001/jama.2019.8430
41. Kast K, Schmutzler RK, Rhiem K, et al. Validation of the Manchester scoring system for predicting *BRCA1/2* mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. *Int J Cancer*. 2014;135(10):2352-2361. doi:10.1002/ijc.28875
42. Biswas S, Atienza P, Chipman J, et al. A two-stage approach to genetic risk assessment in primary care. *Breast Cancer Res Treat*. 2016;155(2):375-383. doi:10.1007/s10549-016-3686-2
43. Albada A, van Dulmen S, Dijkstra H, Wiefier I, Witkamp A, Ausems MG. Counselors' expressed level of understanding of the risk estimate and surveillance recommendation are not associated with breast cancer surveillance adherence. *J Genet Couns*. 2016;25(2):279-289. doi:10.1007/s10897-015-9869-x
44. Bowen DJ, Burke W, Yasui Y, McTiernan A, McLeran D. Effects of risk counseling on interest in breast cancer genetic testing for lower risk women. *Genet Med*. 2002;4(5):359-365. doi:10.1097/O0125817-200209000-00007
45. Burke W, Culver JO, Bowen D, et al. Genetic counseling for women with an intermediate family history of breast cancer. *Am J Med Genet*. 2000;90(5):361-368. doi:10.1002/(SICI)1096-8628(20000228)90:5<361::AID-AJMG4>3.0.CO;2-8
46. Cull A, Miller H, Porterfield T, et al. The use of videotaped information in cancer genetic counselling: a randomized evaluation study. *Br J Cancer*. 1998;77(5):830-837. doi:10.1038/bjc.1998.135
47. Lerman C, Narod S, Schulman K, et al. *BRCA1* testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. *JAMA*. 1996;275(24):1885-1892. doi:10.1001/jama.1996.03530480027036
48. Bowen DJ, Burke W, McTiernan A, Yasui Y, Andersen MR. Breast cancer risk counseling improves women's functioning. *Patient Educ Couns*. 2004;53(1):79-86. doi:10.1016/S0738-3991(03)00122-8
49. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of *BRCA1/2* testing among women with a family history of breast or ovarian cancer. *JAMA*. 2005;293(14):1729-1736. doi:10.1001/jama.293.14.1729
50. Bennett P, Wilkinson C, Turner J, et al. Factors associated with intrusive cancer-related worries in women undergoing cancer genetic risk assessment [published correction appears in *Fam Cancer*. 2009;8(3):263]. *Fam Cancer*. 2009;8(2):159-165. doi:10.1007/s10689-008-9221-9
51. Bennett P, Wilkinson C, Turner J, et al. Psychological factors associated with emotional responses to receiving genetic risk information. *J Genet Couns*. 2008;17(3):234-241. doi:10.1007/s10897-007-9136-x
52. Bloom JR, Stewart SL, Chang S, You M. Effects of a telephone counseling intervention on sisters of young women with breast cancer. *Prev Med*. 2006; 43(5):379-384. doi:10.1016/j.jym.2006.07.002
53. Bowen DJ, Burke W, Culver JO, Press N, Crystal S. Effects of counseling Ashkenazi Jewish women about breast cancer risk. *Cultur Divers Ethnic Minor Psychol*. 2006;12(1):45-56. doi:10.1037/1099-9809.12.1.45
54. Brain K, Parsons E, Bennett P, Cannings-John R, Hood K. The evolution of worry after breast cancer risk assessment: 6-year follow-up of the TRACE study cohort. *Psychooncology*. 2011;20(9):984-991.
55. Braithwaite D, Sutton S, Mackay J, Stein J, Emery J. Development of a risk assessment tool for women with a family history of breast cancer. *Cancer Detect Prev*. 2005;29(5):433-439. doi:10.1016/j.cdp.2005.06.001
56. Fry A, Cull A, Appleton S, et al. A randomised controlled trial of breast cancer genetics services in South East Scotland: psychological impact. *Br J Cancer*. 2003;89(4):653-659. doi:10.1038/sj.bjc.6601170
57. Gurmankin AD, Domchek S, Stopfer J, Fels C, Armstrong K. Patients' resistance to risk information in genetic counseling for *BRCA1/2*. *Arch Intern Med*. 2005;165(5):523-529. doi:10.1001/archinte.165.5.523
58. Helmes AW, Culver JO, Bowen DJ. Results of a randomized study of telephone versus in-person breast cancer risk counseling. *Patient Educ Couns*. 2006;64(1-3):96-103. doi:10.1016/j.pec.2005.12.002
59. Hopwood P, Wonderling D, Watson M, et al. A randomised comparison of UK genetic risk counselling services for familial cancer: psychosocial outcomes. *Br J Cancer*. 2004;91(5):884-892. doi:10.1038/sj.bjc.6602081
60. Kelly KM, Senter L, Leventhal H, Ozakinci G, Porter K. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for *BRCA1/2* mutations. *Patient Educ Couns*. 2008;70(1):135-142. doi:10.1016/j.pec.2007.09.007
61. Matloff ET, Moyer A, Shannon KM, Niendorf KB, Col NF. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making. *J Womens Health (Larchmt)*. 2006;15(7):843-856. doi:10.1089/jwh.2006.15.843
62. Mikkelsen EM, Sunde L, Johansen C, Johnsen SP. Risk perception among women receiving genetic counseling: a population-based follow-up study. *Cancer Detect Prev*. 2007;31(6):457-464. doi:10.1016/j.cdp.2007.10.013
63. Mikkelsen EM, Sunde L, Johansen C, Johnsen SP. Psychosocial consequences of genetic counseling: a population-based follow-up study. *Breast J*. 2009;15(1):61-68. doi:10.1111/j.1524-4741.2008.00672.x
64. Pieterse AH, Ausems MG, Spreeuwenberg P, van Dulmen S. Longer-term influence of breast cancer genetic counseling on cognitions and distress: smaller benefits for affected versus unaffected women. *Patient Educ Couns*. 2011;85(3):425-431. doi:10.1016/j.pec.2011.01.017
65. Roshanai AH, Rosenquist R, Lampic C, Nordin K. Does enhanced information at cancer genetic counseling improve counselees' knowledge, risk perception, satisfaction and negotiation of information to at-risk relatives?—a randomized study. *Acta Oncol*. 2009;48(7):999-1009. doi:10.1080/02841860903104137

66. Smerecnik CM, Mestres I, Verweij E, de Vries NK, de Vries H. A systematic review of the impact of genetic counseling on risk perception accuracy. *J Genet Couns*. 2009;18(3):217-228. doi:10.1007/s10897-008-9210-z
67. Brain K, Norman P, Gray J, Rogers C, Mansel R, Harper P. A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk. *Br J Cancer*. 2002;86(2):233-238. doi:10.1038/sj.bjc.6600051
68. Hopwood P, Keeling F, Long A, Pool C, Evans G, Howell A. Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. *Psychooncology*. 1998;7(5):402-412. doi:10.1002/(SICI)1099-1611(199809)7:5<402::AID-PON317>3.0.CO;2-X
69. Lerman C, Schwartz MD, Miller SM, Daly M, Sands C, Rimer BK. A randomized trial of breast cancer risk counseling: interacting effects of counseling, educational level, and coping style. *Health Psychol*. 1996;15(2):75-83. doi:10.1037/0278-6133.15.2.75
70. Lobb EA, Butow PN, Barratt A, et al. Communication and information-giving in high-risk breast cancer consultations: influence on patient outcomes. *Br J Cancer*. 2004;90(2):321-327. doi:10.1038/sj.bjc.6601502
71. Watson M, Lloyd S, Davidson J, et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. *Br J Cancer*. 1999;79(5-6):868-874. doi:10.1038/sj.bjc.6609139
72. Watson M, Duvivier V, Wade Walsh M, et al. Family history of breast cancer: what do women understand and recall about their genetic risk? *J Med Genet*. 1998;35(9):731-738. doi:10.1136/jmg.35.9.731
73. Livaudais-Toman J, Karlner LS, Tice JA, et al. Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: a randomized, controlled trial. *Breast*. 2015;24(6):758-766. doi:10.1016/j.breast.2015.09.009
74. Lerman C, Hughes C, Benkendorf JL, et al. Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. *Cancer Epidemiol Biomarkers Prev*. 1999;8(4, pt 2):361-367.
75. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. *J Natl Cancer Inst*. 2014;107(1):379.
76. Julian-Reynier C, Mancini J, Mouret-Fourme E, et al. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. *Eur J Hum Genet*. 2011;19(5):500-506. doi:10.1038/ejhg.2010.241
77. Lumish HS, Steinfeld H, Koval C, et al. Impact of panel gene testing for hereditary breast and ovarian cancer on patients. *J Genet Couns*. 2017;26(5):1116-1129. doi:10.1007/s10897-017-0090-y
78. Nelson HD, Fu R, McDonagh M, Miller LB, Pappas M, Zakher B. *Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the US Preventive Services Task Force*. Rockville, MD: Agency for Healthcare Research and Quality; 2019.
79. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst*. 2005;97(22):1652-1662. doi:10.1093/jnci/dji372
80. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. *J Natl Cancer Inst*. 2007;99(4):283-290. doi:10.1093/jnci/djk050
81. Veronesi U, Maisonneuve P, Rotmensz N, et al; Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. *J Natl Cancer Inst*. 2007;99(9):727-737. doi:10.1093/jnci/djk154
82. Cuzick J, Forbes JF, Sestak I, et al; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. *J Natl Cancer Inst*. 2007;99(4):272-282. doi:10.1093/jnci/djk049
83. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. *Clin Cancer Res*. 2006;12(17):5242-5247. doi:10.1158/1078-0432.CCR-06-0688
84. Grady D, Cauley JA, Geiger MJ, et al; Raloxifene Use for The Heart Trial Investigators. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. *J Natl Cancer Inst*. 2008;100(12):854-861. doi:10.1093/jnci/djn153
85. Cuzick J, Sestak I, Forbes JF, et al; IBIS-II Investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet*. 2014;383(9922):1041-1048. doi:10.1016/S0140-6736(13)62292-8
86. Goss PE, Ingle JN, Alés-Martínez JE, et al; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med*. 2011;364(25):2381-2391. doi:10.1056/NEJMoa1103507
87. Sestak I, Singh S, Cuzick J, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risenedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial [published correction appears in *Lancet Oncol*. 2014;15(13):e587]. *Lancet Oncol*. 2014;15(13):1460-1468. doi:10.1016/S1470-2045(14)71035-6
88. Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II prevention trial. *J Clin Oncol*. 2016;34(2):139-143. doi:10.1200/JCO.2015.63.4972
89. Maunsell E, Goss PE, Chlebowski RT, et al. Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. *J Clin Oncol*. 2014;32(14):1427-1436. doi:10.1200/JCO.2013.51.2483
90. Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. *Cancer Prev Res (Phila)*. 2010;3(6):696-706. doi:10.1158/1940-6207.CAPR-10-0076
91. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA*. 2010;304(9):967-975. doi:10.1001/jama.2010.1237
92. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med*. 1999;340(2):77-84. doi:10.1056/NEJM199901143400201
93. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J Natl Cancer Inst*. 2001;93(21):1633-1637. doi:10.1093/jnci/93.21.1633
94. Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres. *J Med Genet*. 2009;46(4):254-258. doi:10.1136/jmg.2008.062232
95. Skytte AB, Crüger D, Gerster M, et al. Breast cancer after bilateral risk-reducing mastectomy. *Clin Genet*. 2011;79(5):431-437. doi:10.1111/j.1399-0004.2010.01604.x
96. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. *Ann Oncol*. 2013;24(8):2029-2035. doi:10.1093/annonc/mdt134
97. Flippo-Morton T, Walsh K, Chambers K, et al. Surgical decision making in the BRCA-positive population: institutional experience and comparison with recent literature. *Breast J*. 2016;22(1):35-44. doi:10.1111/tbj.12521
98. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. *J Clin Oncol*. 2005;23(34):8629-8635. doi:10.1200/JCO.2005.02.9199
99. Olson JE, Sellers TA, Iturria SJ, Hartmann LC. Bilateral oophorectomy and breast cancer risk reduction among women with a family history. *Cancer Detect Prev*. 2004;28(5):357-360. doi:10.1016/j.cdp.2004.03.003
100. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. *J Natl Cancer Inst Monogr*. 1995;(17):33-35.
101. Mavaddat N, Peock S, Frost D, et al; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst*. 2013;105(11):812-822. doi:10.1093/jnci/djt095
102. Shah P, Rosen M, Stopfer J, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. *Breast Cancer Res Treat*. 2009;118(3):539-546. doi:10.1007/s10549-009-0475-1
103. Rebbeck TR, Lynch HT, Neuhausen SL, et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med*.

2002;346(21):1616-1622. doi:10.1056/NEJMoa012158

- 104.** Kotsopoulos J, Huzarski T, Gronwald J, et al; Hereditary Breast Cancer Clinical Study Group. Bilateral oophorectomy and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers [published online September 6, 2016]. *J Natl Cancer Inst.* 2016;109(1). doi:10.1093/jnci/djw177
- 105.** Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al; Hereditary Breast and Ovarian Cancer Research Group Netherlands. Breast cancer risk after salpingo-oophorectomy in healthy *BRCA1/2* mutation carriers: revisiting the evidence for risk reduction [published online March 18, 2015]. *J Natl Cancer Inst.* 2015;107(5):djv033. doi:10.1093/jnci/djv033
- 106.** Lieberman S, Tomer A, Ben-Chetrit A, et al. Population screening for *BRCA1/BRCA2* founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. *Genet Med.* 2017;19(7):754-762. doi:10.1038/gim.2016.182
- 107.** Smith KR, West JA, Croyle RT, Botkin JR. Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after *BRCA1* mutation testing. *Cancer Epidemiol Biomarkers Prev.* 1999;8(4, pt 2):385-392.
- 108.** Dagan E, Shochat T. Quality of life in asymptomatic *BRCA1/2* mutation carriers. *Prev Med.* 2009;48(2):193-196. doi:10.1016/j.pymed.2008.11.007
- 109.** van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. *J Clin Oncol.* 2006;24(22):3672-3677. doi:10.1200/JCO.2005.03.7259
- 110.** Metcalfe KA, Mian N, Enmore M, et al. Long-term follow-up of Jewish women with a *BRCA1* and *BRCA2* mutation who underwent population genetic screening. *Breast Cancer Res Treat.* 2012;133(2):735-740. doi:10.1007/s10549-011-1941-0
- 111.** Meiser B, Butow P, Friedlander M, et al. Psychological impact of genetic testing in women from high-risk breast cancer families. *Eur J Cancer.* 2002;38(15):2025-2031. doi:10.1016/S0959-8049(02)00264-2
- 112.** Andrews L, Meiser B, Apicella C, Tucker K. Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. *Genet Test.* 2004;8(3):240-247. doi:10.1089/gte.2004.8.240
- 113.** Foster C, Watson M, Eeles R, et al; Psychosocial Study Collaborators. Predictive genetic testing for *BRCA1/2* in a UK clinical cohort: three-year follow-up. *Br J Cancer.* 2007;96(5):718-724. doi:10.1038/sj.bjc.6603610
- 114.** Low CA, Bower JE, Kwan L, Seldon J. Benefit finding in response to *BRCA1/2* testing. *Ann Behav Med.* 2008;35(1):61-69. doi:10.1007/s12160-007-9004-9
- 115.** Arver B, Haegermark A, Platten U, Lindblom A, Brandberg Y. Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up. *Fam Cancer.* 2004;3(2):109-116. doi:10.1023/B:FAME.0000039863.89137.f9

- 116.** Ertmariski S, Metcalfe K, Trempala J, et al. Identification of patients at high risk of psychological distress after *BRCA1* genetic testing. *Genet Test Mol Biomarkers.* 2009;13(3):325-330. doi:10.1089/gtmb.2008.0126
- 117.** Reichelt JG, Møller P, Heimdal K, Dahl AA. Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated *BRCA1* mutations for hereditary breast/ovarian cancer. *Fam Cancer.* 2008;7(3):245-254. doi:10.1007/s10689-008-9182-z
- 118.** Reichelt JG, Heimdal K, Møller P, Dahl AA. *BRCA1* testing with definitive results: a prospective study of psychological distress in a large clinic-based sample. *Fam Cancer.* 2004;3(1):21-28. doi:10.1023/B:FAME.0000026820.32469.4a
- 119.** Geirdal AO, Dahl AA. The relationship between coping strategies and anxiety in women from families with familial breast-ovarian cancer in the absence of demonstrated mutations. *Psychooncology.* 2008;17(1):49-57. doi:10.1002/pon.1198
- 120.** Geirdal AO, Reichelt JG, Dahl AA, et al. Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations. *Fam Cancer.* 2005;4(2):121-126. doi:10.1007/s10689-004-7995-y
- 121.** Le-Petross HT, Whitman GJ, Atchley DP, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious *BRCA* mutations at high risk of breast cancer. *Cancer.* 2011;117(17):3900-3907. doi:10.1002/cncr.25971
- 122.** Kriege M, Brekelmans CT, Boetes C, et al; Dutch MRI Screening (MRISC) Study Group. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. *Cancer.* 2006;106(11):2318-2326. doi:10.1002/cncr.21863
- 123.** Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. *BMJ.* 1993;306(6884):1025-1029. doi:10.1136/bmj.306.6884.1025
- 124.** Hermesen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in *BRCA1/2* mutation carriers; an observational follow-up study. *Br J Cancer.* 2007;96(9):1335-1342. doi:10.1038/sj.bjc.6603725
- 125.** Spiegel TN, Esplen MJ, Hill KA, Wong J, Causer PA, Warner E. Psychological impact of recall on women with *BRCA* mutations undergoing MRI surveillance. *Breast.* 2011;20(5):424-430. doi:10.1016/j.breast.2011.04.004
- 126.** Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. *Ann Intern Med.* 2009;151(10):703-715. doi:10.7326/0000605-200911170-00147
- 127.** Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2013;158(8):604-614. doi:10.7326/0003-4819-158-8-201304160-00005

- 128.** Arver B, Isaksson K, Atterhem H, et al. Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. *Ann Surg.* 2011;253(6):1147-1154. doi:10.1097/SLA.0b013e318214b55a
- 129.** Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in *BRCA1/2* mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. *Ann Surg Oncol.* 2007;14(12):3335-3344. doi:10.1245/s10434-007-9449-x
- 130.** Alamouti R, Hachach-Haram N, Farhadi J. Multidisciplinary management of risk-reducing mastectomy and immediate reconstruction: treatment algorithm and patient satisfaction. *J Plast Reconstr Aesthet Surg.* 2015;38(5):385-390.
- 131.** Nurudeen S, Guo H, Chun Y, et al. Patient experience with breast reconstruction process following bilateral mastectomy in *BRCA* mutation carriers. *Am J Surg.* 2017;214(4):687-694. doi:10.1016/j.amjsurg.2017.06.017
- 132.** den Heijer M, Seynaeve C, Timman R, et al. Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. *Eur J Cancer.* 2012;48(9):1263-1268. doi:10.1016/j.ejca.2011.10.020
- 133.** Gopie JP, Mureau MA, Seynaeve C, et al. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. *Fam Cancer.* 2013;12(3):479-487. doi:10.1007/s10689-012-9588-5
- 134.** Isern AE, Tengrup I, Loman N, Olsson H, Ringberg A. Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. *J Plast Reconstr Aesthet Surg.* 2008;61(10):1177-1187. doi:10.1016/j.bjps.2007.08.006
- 135.** Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. *Prev Med.* 1995;24(4):412-419. doi:10.1006/pmed.1995.1066
- 136.** Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. *J Clin Oncol.* 2008;26(24):3943-3949. doi:10.1200/JCO.2007.13.9568
- 137.** Gahm J, Wickman M, Brandberg Y. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer—prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. *Breast.* 2010;19(6):462-469. doi:10.1016/j.breast.2010.05.003
- 138.** Brandberg Y, Arver B, Johansson H, Wickman M, Sandelin K, Liljegren A. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study. *Eur J Surg Oncol.* 2012;38(1):38-43. doi:10.1016/j.ejso.2011.10.010
- 139.** Wasteson E, Sandelin K, Brandberg Y, Wickman M, Arver B. High satisfaction rate ten years after bilateral prophylactic mastectomy—a longitudinal study. *Eur J Cancer Care (Engl).* 2011;20(4):508-513. doi:10.1111/j.1365-2354.2010.01204.x

- 140.** Metcalfe KA, Esplen MJ, Goel V, Narod SA. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. *Psychooncology*. 2004;13(1):14-25. doi:10.1002/pon.726
- 141.** Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a *BRCA* mutation. *Gynecol Oncol*. 2011;121(1):163-168. doi:10.1016/j.ygyno.2010.12.326
- 142.** Kenkhuis MJ, de Bock GH, Elferink PO, et al. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in *BRCA1/2* mutation carriers. *Maturitas*. 2010;66(3):310-314. doi:10.1016/j.maturitas.2010.03.018
- 143.** Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. *Int J Gynecol Cancer*. 2009;19(6):1029-1036. doi:10.1111/IGC.Ob013e3181a83cd5
- 144.** Bresser PJ, Seynaeve C, Van Gool AR, et al. The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. *Eur J Cancer*. 2007;43(1):95-103. doi:10.1016/j.ejca.2006.09.009
- 145.** Borreani C, Manoukian S, Bianchi E, et al. The psychological impact of breast and ovarian cancer preventive options in *BRCA1* and *BRCA2* mutation carriers. *Clin Genet*. 2014;85(1):7-15. doi:10.1111/cge.12298
- 146.** Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a *BRCA* mutation: a review. *Maturitas*. 2011;70(3):261-265. doi:10.1016/j.maturitas.2011.08.001
- 147.** U.S. Preventive Services Task Force. Genetic risk assessment and *BRCA* mutation testing for breast and ovarian cancer susceptibility: recommendation statement. *Ann Intern Med*. 2005;143(5):355-361. doi:10.7326/0003-4819-143-5-200509060-00011
- 148.** American College of Medical Genetics. *Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling, and Testing Guidelines*. Bethesda, MD: American College of Medical Genetics; 1999.
- 149.** American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. *J Clin Oncol*. 1996;14(5):1730-1736. doi:10.1200/JCO.1996.14.5.1730
- 150.** Committee opinion no. 634: hereditary cancer syndromes and risk assessment. *Obstet Gynecol*. 2015;125(6):1538-1543. doi:10.1097/O1.AOG.0000466373.71146.51
- 151.** Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol*. 2015;136(1):3-7. doi:10.1016/j.ygyno.2014.09.009
- 152.** American Society of Breast Surgeons (ASBrS). Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. ASBrS website. <https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf>. Accessed July 3, 2019.
- 153.** National Institute for Health and Care Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE website. <https://www.nice.org.uk/guidance/cg164/chapter/Recommendations>. Published June 2013. Accessed July 3, 2019.
- 154.** Paluch-Shimon S, Cardoso F, Sessa C, et al; ESMO Guidelines Committee. Prevention and screening in *BRCA* mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. *Ann Oncol*. 2016;27(suppl 5):v103-v110. doi:10.1093/annonc/mdw327